BRAF and colorectal carcinoma: Examples of such clinical applications include the use of anti- vascular endothelial growth factor (VEGF) monoclonal antibodies (mAb) (i.e., bevacizumab) in metastatic CRC (mCRC) or anti-epidermal growth factor receptor (EGFR) mAb (i.e., cetuximab) in panRAS and BRAF wild type (wt) CRC [13].